1-3 of 3
Ling Li
Close
Sort by
Journal Articles

CG001, a C3b-targeted complement inhibitor blocks three complement pathways: development and preclinical evaluation

Ling Li, Peipei Ding, Yanrong Dong, Shupei Shen, Xinyue Lv, Jie Yu, Luying Li, Jianfeng Chen, Pilin Wang, Bing Han, Ting Xu, Weiguo Hu
Journal: Blood Advances
Blood Adv bloodadvances.2024012874.
https://doi.org/10.1182/bloodadvances.2024012874
Published: 2024
Includes: Supplemental data
Journal Articles

Overexpression of WT1 and PRAME predicts poor outcomes of patients with myelodysplastic syndromes with thrombocytopenia

Clinical Trials & Observations
Qiu-Sha Huang, Jing-Zhi Wang, Ya-Zhen Qin, Qiao-Zhu Zeng, Qian Jiang, Hao Jiang, Jin Lu, Hui-Xin Liu, Yi Liu, Jing-Bo Wang, Li Su, Hong-Yu Zhang, Zhen-Ling Li, Su-Jun Gao, Bo Huang, Yu-Ying Liu, Yan-Rong Liu, Lan-Ping Xu, Xiao-Jun Huang, Xiao-Hui Zhang
Journal: Blood Advances
Blood Adv (2019) 3 (21): 3406–3418.
https://doi.org/10.1182/bloodadvances.2019000564
Published: 2019
Includes: Supplemental data
Journal Articles

Defining the epigenetic status of blood cells using a cyanine-based fluorescent probe for PRMT1

Hairui Su, Chiao-Wang Sun, Szu-Mam Liu, Xin He, Hao Hu, Kevin M. Pawlik, Tim M. Townes, Xiaosi Han, Christopher A. Klug, Maged Henary, Yabing Chen, Ling Li, Y. George Zheng, Xinyang Zhao
Journal: Blood Advances
Blood Adv (2018) 2 (21): 2829–2836.
https://doi.org/10.1182/bloodadvances.2018020727
Published: 2018
Includes: Supplemental data